Rezolute, Inc. (RZLT)
| Market Cap | 50.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.79M |
| Shares Out | 36.83M |
| EPS (ttm) | -1.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,079 |
| Open | 1.35 |
| Previous Close | 1.35 |
| Day's Range | 1.34 - 1.41 |
| 52-Week Range | 1.30 - 2.97 |
| Beta | 2.13 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+708.82%) |
| Earnings Date | Nov 8, 2023 |
About RZLT
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as Ant... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 708.82% from the latest price.
News
Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress
Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023
Rezolute to Participate in Upcoming Investor Conferences in September
REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t...
Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism
Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET REDWOOD CITY, Calif.
Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease
Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innov...
Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress
The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye RZ402 is an oral therapy being developed as a potential alternati...
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert
Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
Initiated Phase 2 proof-of-concept study of RZ402
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye RZ402 is an oral therapy being developed as a potential alternative to invasive a...
Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress
Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year
Rezolute to Present at the Jefferies London Healthcare Conference
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress
Announced a $130 million registered direct offering and concurrent private placement priced at-the-market
Rezolute Announces Presentation at the 60th Annual ESPE Meeting
Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation
Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer
REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...
Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Announced a $130 million registered direct offering and concurrent private placement
Rezolute to Host Corporate Update Call on May 4, 2022
Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET
Rezolute, Inc. Announces Closing of Registered Direct Offering
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to ...
Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market
REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to ...
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting
RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022
Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET
Rezolute Joins the Rare Disease Company Coalition
Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving ther...
Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism
The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability
Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME
Phase 2 proof-of-concept study anticipated in 2H 2022 Phase 2 proof-of-concept study anticipated in 2H 2022
Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress
Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022